An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Accumulating evidence suggests a role of G protein-coupled inwardly-rectifying potassium
(GIRK) channel in the pathology of excitement of nerve, and the medicine with the action
(like the Tipepidine Hibenzate) is expected as a new curative medicine of Attention Deficit /
Hyperactivity Disorder (AD/HD).
The purpose of this research is to confirm the effect by carrying out the additional dosage
of the Tipepidine Hibenzate to the AD/HD patients.
If suggestion is obtained by this research about the effect on AD/HD of Tipepidine Hibenzate,
it can contribute to development of the medical treatment of AD/HD.